SEATTLE, May 10 /PRNewswire/ -- Coronado Biosciences, Inc., a Company focused on the development and commercialization of therapeutic products for the treatment of cancer, announced today the appointment of Gary G. Gemignani as chief operating officer and chief financial officer.   Effective today, Mr. Gemignani will be responsible for operational and business development activities and financial management for Coronado Biosciences.  

Mr. Gemignani brings to Coronado 25 years of accounting, strategic planning and finance experience that includes employment at a broad spectrum of life science businesses including emerging biotech, big pharma and accounting and consultancy.  Mr. Gemignani was most recently executive vice president and chief financial officer at Gentium S.p.A., a publicly traded, late-stage biotechnology Company focused on the development and manufacturing of drugs to treat and prevent vascular diseases related to cancer.  Prior to joining Gentium, Mr. Gemignani held senior financial positions at Novartis, Prudential Financial, Wyeth and Arthur Andersen & Co.  

"Gary brings operational leadership and finance and management expertise to the Company's Executive Management Team," said RJ Tesi, M.D., president and chief executive officer of Coronado.   "His range of experience working with both large biotech and emerging life science companies will contribute to the long-term success of Coronado."

Commenting on his appointment, Mr. Gemignani remarked, "I am pleased to be working with Coronado as the Company moves their compounds from early to late stage clinical development.  Given Coronado's unique technology, I believe there is substantial value to be unlocked and look forward to working with the management and board to accomplish the Company's goals."

About Coronado Biosciences, Inc.

Coronado Biosciences, Inc. is a private, clinical stage company that is focused on the development of therapeutic products for the treatment of cancer.  Coronado has three programs; cndo102 activated NK cells for the treatment of relapsed/refractory AML, cndo101, a 4th generation doxorubicin analogue for the treatment of women with breast cancer who have the CAP17 duplication, and C1, a pan Bcl-2 inhibitor program.  The cndo102 and cndo101 are in Phase I clinical trials, the C1 program is expected enter the clinic soon.  Coronado was founded in 2007.  For more information, please visit www.coronadobiosciences.com

Note:  This press release contains forward looking statements that are based upon management's current expectations and are inherently uncertain. Actual results and timing of events could differ materially from current expectations and forward-looking statements.

SOURCE Coronado Biosciences, Inc.

Back to top

RELATED LINKS
http://www.coronadobiosciences.com